AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 191 min read$MCK

Fraga Francisco sold $797K of MCK

Fraga Francisco (EVP, CIO and CTO) sold 800 shares of MCKESSON CORP (MCK) at $995.80 ($0.80M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fraga Francisco
Published Oct 19, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, likely exerting limited price influence.

02

Market read

A routine insider sale with modest size; low immediate trading relevance.

03

What to watch

Potential tax planning or diversification motives behind the 10b5‑1 execution.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

SEC Form 4 shows EVP/CTO sold 800 shares for $797,128, a direct insider sale via 10b5‑1 plan.

Expected impact

potential slight downward pressure as market prices in the sale.

Evidence & confidence

The sale is modest relative to holdings (5,423 shares) and executed under a pre‑arranged plan, limiting informational content.

Market effects

Sector

Minimal impact on healthcare distribution sector; insider activity is routine.

Regional

No broader regional effect.

Global

Limited to investors tracking McKesson.

Counterpoint

What could challenge this read

Sale could be unrelated to fundamentals; price may remain unchanged.

Key entities

  • Officer
    Fraga Francisco

    EVP, CIO and CTO of McKesson Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MCK insider trading history →

Related articles

OCT 27
$MCKLow

Built and Bred

McKesson (MCK) will invest $179M in a 330,000 sq. ft. regional distribution center in Moore, Oklahoma, creating 200+ jobs. The site's location, readiness, and regional coordination influenced the decision, according to the company.

citylifestyle.com2 min
OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 8
$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

healthcare-digital.com3 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min